Turn­ing Point touts pos­i­tive piv­otal NSCLC da­ta, hints at even faster OK — but can it beat Pfiz­er and Roche?

Turn­ing Point Ther­a­peu­tics has long set a clear goal to shoot for an ac­cel­er­at­ed ap­proval of re­potrec­tinib, its ty­ro­sine ki­nase in­hibitor for ROS1- or NTRK …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER